BIOVOICE DENMARK ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  23.3% 25.7% 5.7% 9.9% 17.1%  
Credit score (0-100)  4 3 39 24 9  
Credit rating  B B BBB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  5,133 5,685 0 0 0  
Gross profit  215 327 438 319 153  
EBITDA  7.4 29.8 48.7 -119 10.5  
EBIT  7.4 29.8 48.7 -119 -33.8  
Pre-tax profit (PTP)  -24.2 12.4 31.3 -119.2 -35.4  
Net earnings  -24.2 12.4 31.3 -119.2 -35.4  
Pre-tax profit without non-rec. items  -24.2 12.4 31.3 -119 -35.4  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  78.7 123 117 83.9 4.1  
Shareholders equity total  78.5 90.9 184 64.4 29.0  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  262 302 396 99.0 29.0  

Net Debt  -13.1 -9.1 -166 -14.5 -9.3  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  5,133 5,685 0 0 0  
Net sales growth  11.7% 10.8% -100.0% 0.0% 0.0%  
Gross profit  215 327 438 319 153  
Gross profit growth  25.7% 52.4% 33.9% -27.2% -52.0%  
Employees  0 0 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  262 302 396 99 29  
Balance sheet change%  -12.1% 15.4% 31.0% -75.0% -70.7%  
Added value  7.4 29.8 48.7 -119.1 10.5  
Added value %  0.1% 0.5% 0.0% 0.0% 0.0%  
Investments  31 44 -6 -33 -124  

Net sales trend  3.0 4.0 -1.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 -1.0 -2.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.1% 0.5% 0.0% 0.0% 0.0%  
EBIT %  0.1% 0.5% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  3.5% 9.1% 11.1% -37.4% -22.1%  
Net Earnings %  -0.5% 0.2% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  -0.5% 0.2% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  -0.5% 0.2% 0.0% 0.0% 0.0%  
ROA %  2.7% 10.6% 14.0% -47.2% -52.8%  
ROI %  8.2% 35.2% 35.5% -94.1% -72.3%  
ROE %  -26.7% 14.6% 22.8% -96.1% -75.7%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  30.0% 30.1% 46.4% 65.1% 100.0%  
Relative indebtedness %  3.6% 3.7% 0.0% 0.0% 0.0%  
Relative net indebtedness %  3.3% 3.6% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -175.9% -30.6% -340.2% 12.2% -88.6%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.6 0.5 1.0 0.4 0.0  
Current Ratio  0.6 0.5 1.3 0.4 0.0  
Cash and cash equivalent  13.1 9.1 165.8 14.5 9.3  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  2.2% 1.9% 0.0% 0.0% 0.0%  
Net working capital  -70.2 -102.1 66.6 -19.5 24.9  
Net working capital %  -1.4% -1.8% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 49 -119 11  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 49 -119 11  
EBIT / employee  0 0 49 -119 -34  
Net earnings / employee  0 0 31 -119 -35